知镜 Cognispect · 医学文献与研究工作台

Familial pulmonary alveolar proteinosis and type I interferonopathy by mutation of STAT2 (TIMS2).

Gruber C, Ramba M, Debnath B, Cuollo L, Neehus AL, Lee A, Buta S, Martin-Fernandez M, Rosain J, Berteloot L, Drabent P, Le Voyer T, Soudée C, Peel J, Seeleuthner Y, Puel A, Zhang SY, Ciancanelli MJ, Arango-Franco CA, Migaud M, Frémond ML, Renaldo F, Boespflug-Tanguy O, Dorboz I, Dubern B, Fonteneau T, Parvaneh N, Molatefi R, Shahrooei M, Duffy D, Bondet V, Rice GI, Crow YJ, Molina TJ, Boddaert N, Casanova JL, Houdouin V, Melki I, Hadchouel A, Bustamante J, Bogunovic D.
The Journal of experimental medicine · 2026-07-16 · PMID 42461263

文献摘要

Mutations that enhance type I interferon (IFN-I) activity cause monogenic autoinflammatory disorders termed type I interferonopathies. Along with the typical neurologic and rheumatologic manifestations, severe pulmonary disease is increasingly recognized yet poorly understood. We studied three siblings presenting with early-onset, life-threatening pulmonary alveolar proteinosis (PAP) and autoinflammatory stigmata. Genetic analysis uncovered a novel homozygous variant (R223Q) in STAT2, a key mediator of IFN-I signaling, which also facilitates feedback inhibition via USP18. R223Q STAT2 preserved signal transduction and viral control in vitro. However, cells homozygous for the R223Q variant failed to terminate IFN-I responses, owing to impaired localization of USP18. Unlike in classical forms of PAP, GM-CSF signaling remained intact. Instead, persistent IFN-I signaling antagonized monocyte migration toward chemokines essential for lung trafficking. Informed by these findings, the youngest sibling received JAK inhibitor and anti-IFN-I receptor therapy with marked clinical improvement. Collectively, type I interferonopathy by mutation of STAT2 (TIMS2) compromises monocyte chemotaxis and underlies a novel mechanism of PAP.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。